Zymeworks Inc (ZYME) Receives $14.35 Consensus PT from Analysts

Zymeworks Inc (NYSE:ZYME) has been assigned a consensus rating of “Hold” from the seven ratings firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $16.00.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Zymeworks from a “buy” rating to a “hold” rating in a research note on Saturday. Cormark restated a “buy” rating on shares of Zymeworks in a research note on Saturday, September 30th.

An institutional investor recently bought a new position in Zymeworks stock. Franklin Resources Inc. purchased a new position in shares of Zymeworks Inc (NYSE:ZYME) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 823,700 shares of the company’s stock, valued at approximately $6,878,000. Franklin Resources Inc. owned about 3.30% of Zymeworks as of its most recent SEC filing. Hedge funds and other institutional investors own 7.20% of the company’s stock.

Shares of Zymeworks (NYSE ZYME) traded up $0.13 during mid-day trading on Wednesday, hitting $9.52. 15,081 shares of the stock traded hands, compared to its average volume of 15,040. Zymeworks has a 12 month low of $6.25 and a 12 month high of $14.25. The stock has a market cap of $241.59 and a price-to-earnings ratio of -4.19.

COPYRIGHT VIOLATION NOTICE: This article was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/01/13/zymeworks-inc-zyme-receives-14-35-consensus-pt-from-analysts.html.

Zymeworks Company Profile

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.

Analyst Recommendations for Zymeworks (NYSE:ZYME)

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply